{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:20:10Z","timestamp":1764181210434,"version":"3.46.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05445-z","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:04:14Z","timestamp":1763985854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eschweilenol C and subfractions from Terminalia plants disrupt haemoglobin metabolism, inhibiting Plasmodium falciparum growth at rings and trophozoite stages"],"prefix":"10.1186","volume":"24","author":[{"given":"Mariscal Brice Tchatat","family":"Tali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric Derick Jiatsa","family":"Mbouna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aafreen","family":"Zehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Collins Njonte","family":"Wouamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy Paulin Kemayou","family":"Mouthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubin Youbi","family":"Kamche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darline","family":"Dize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon Fogue","family":"Kouam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boniface Pone","family":"Kamdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Claude","family":"Tchouankeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feroz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice Fekam","family":"Boyom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"5445_CR1","unstructured":"WHO. World Malaria Report 2024. Geneva: World Health Organization; 2024."},{"key":"5445_CR2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5445_CR3","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"5445_CR4","first-page":"1","volume":"3099","author":"PJ Rosenthal","year":"2024","unstructured":"Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024;3099:1\u201310.","journal-title":"Lancet Infect Dis"},{"key":"5445_CR5","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","volume":"3","author":"MA Phillips","year":"2017","unstructured":"Phillips MA, Burrows JN, Manyando C, Van HRH, Van VWC, Wells TNC. Malaria Nat Rev Dis Primers. 2017;3:17050.","journal-title":"Malaria Nat Rev Dis Primers"},{"key":"5445_CR6","first-page":"2053","volume":"125","author":"MK Dearnley","year":"2012","unstructured":"Dearnley MK, Yeoman JA, Hanssen E, Kenny S, Turnbull L, Whitchurch CB, et al. Origin, composition, organization and function of the inner membrane complex of Plasmodium falciparum gametocytes. J Cell Sci. 2012;125:2053\u201363.","journal-title":"J Cell Sci"},{"key":"5445_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/cmi.12413","volume":"17","author":"RE Sinden","year":"2015","unstructured":"Sinden RE. The cell biology of malaria infection of the mosquito: advances and opportunities. Cell Microbiol. 2015;17:451\u201366.","journal-title":"Cell Microbiol"},{"key":"5445_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI98012","volume":"128","author":"KA Collins","year":"2018","unstructured":"Collins KA, Wang CYT, Adams M, Mitchell H, Rampton M, Elliott S, et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. J Clin Invest. 2018;128:1551\u201362.","journal-title":"J Clin Invest"},{"key":"5445_CR9","doi-asserted-by":"publisher","first-page":"649184","DOI":"10.3389\/fcell.2021.649184","volume":"9","author":"NA Counihan","year":"2021","unstructured":"Counihan NA, Modak JK, de Koning-Ward TF. How malaria parasites acquire nutrients from their host. Front Cell Dev Biol. 2021;9:649184.","journal-title":"Front Cell Dev Biol"},{"key":"5445_CR10","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1073\/pnas.87.8.2931","volume":"87","author":"DE Goldberg","year":"1990","unstructured":"Goldberg DE, Slater AF, Cerami A, Henderson GB. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci USA. 1990;87:2931\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5445_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tibs.2009.08.004","volume":"35","author":"TS Skinner-Adams","year":"2010","unstructured":"Skinner-Adams TS, Stack CM, Trenholme KR, Brown CL, Grembecka J, Lowther J, et al. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends Biochem Sci. 2010;35:53\u201361.","journal-title":"Trends Biochem Sci"},{"key":"5445_CR12","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41598-021-82499-4","volume":"11","author":"R Mathew","year":"2021","unstructured":"Mathew R, Wunderlich J, Thivierge K, Cwiklinski K, Dumont C, Tilley L, et al. Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP). Sci Rep. 2021;11:2854.","journal-title":"Sci Rep"},{"key":"5445_CR13","doi-asserted-by":"publisher","first-page":"e31938","DOI":"10.1371\/journal.pone.0031938","volume":"7","author":"M Poreba","year":"2012","unstructured":"Poreba M, McGowan S, Skinner-Adams TS, Trenholme KR, Gardiner DL, Whisstock JC, et al. Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum. PLoS ONE. 2012;7:e31938.","journal-title":"PLoS ONE"},{"key":"5445_CR14","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1128\/AAC.00060-08","volume":"52","author":"M Henry","year":"2008","unstructured":"Henry M, Briolant S, Fontaine A, Mosnier J, Baret E, Amalvict R, et al. In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2008;52:2755\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"5445_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/cb4008953","volume":"9","author":"CA Hrycyna","year":"2014","unstructured":"Hrycyna CA, Summers RL, Lehane AM, Pires MM, Namanja H, Bohn K, et al. Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum. ACS Chem Biol. 2014;9:722\u201330.","journal-title":"ACS Chem Biol"},{"key":"5445_CR16","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1038\/s41467-023-42030-x","volume":"14","author":"VA Balta","year":"2023","unstructured":"Balta VA, Stiffler D, Sayeed A, Tripathi AK, Elahi R, Mlambo G, et al. Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito. Nat Commun. 2023;14:6415.","journal-title":"Nat Commun"},{"key":"5445_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.coph.2018.06.003","volume":"42","author":"N Suresh","year":"2018","unstructured":"Suresh N, Haldar K. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. Curr Opin Pharmacol. 2018;42:46\u201354.","journal-title":"Curr Opin Pharmacol"},{"key":"5445_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5445_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/QCO.0000000000000766","volume":"34","author":"M Dhorda","year":"2021","unstructured":"Dhorda M, Amaratunga C, Dondorp AM. Artemisinin and multidrug-resistant Plasmodium falciparum\u2014a threat for malaria control and elimination. Curr Opin Infect Dis. 2021;34:432\u20139.","journal-title":"Curr Opin Infect Dis"},{"key":"5445_CR20","doi-asserted-by":"publisher","first-page":"105460","DOI":"10.1016\/j.meegid.2023.105460","volume":"112","author":"WA Azmi","year":"2023","unstructured":"Azmi WA, Rizki AFM, Djuardi Y, Artika IM, Siregar JE. Molecular insights into artemisinin resistance in Plasmodium falciparum: an updated review. Infect Genet Evol. 2023;112:105460.","journal-title":"Infect Genet Evol"},{"key":"5445_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): Do not forget the partner Drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"5445_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijpddr.2021.05.007","volume":"16","author":"FA Siddiqui","year":"2021","unstructured":"Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: emergence, mechanisms, and outlook. Int J Parasitol Drugs Drug Resist. 2021;16:102\u201318.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5445_CR23","doi-asserted-by":"publisher","first-page":"77634","DOI":"10.7554\/eLife.77634","volume":"11","author":"T Masserey","year":"2022","unstructured":"Masserey T, Lee T, Golumbeanu M, Shattock AJ, Kelly SL, Hastings IM, et al. The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant Plasmodium falciparum. Elife. 2022;11:77634.","journal-title":"Elife"},{"key":"5445_CR24","doi-asserted-by":"publisher","first-page":"820650","DOI":"10.3389\/fcimb.2022.820650","volume":"12","author":"S Yu","year":"2022","unstructured":"Yu S, Wang J, Luo X, Zheng H, Wang L, Yang X, et al. Transmission-blocking strategies against malaria parasites during their mosquito stages. Front Cell Infect Microbiol. 2022;12:820650.","journal-title":"Front Cell Infect Microbiol"},{"key":"5445_CR25","doi-asserted-by":"publisher","first-page":"734263","DOI":"10.3389\/fphar.2021.734263","volume":"12","author":"IP Ceravolo","year":"2021","unstructured":"Ceravolo IP, Aguiar AC, Adebayo JO, Krettli AU. Studies on activities and chemical characterization of medicinal plants in search for new antimalarials: a ten year review on ethnopharmacology. Front Pharmacol. 2021;12:734263.","journal-title":"Front Pharmacol"},{"key":"5445_CR26","doi-asserted-by":"publisher","first-page":"115512","DOI":"10.1016\/j.jep.2022.115512","volume":"296","author":"MBT Tali","year":"2022","unstructured":"Tali MBT, Dize D, Njonte Wouamba SC, Tsouh Fokou PV, Keumoe R, Ngansop CN, et al. In vitro antiplasmodial activity-directed investigation and UPLC\u2013MS fingerprint of promising extracts and fractions from Terminalia ivorensis A Chev and Terminalia brownii Fresen. J Ethnopharmacol. 2022;296:115512.","journal-title":"J Ethnopharmacol"},{"key":"5445_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/np980046u","volume":"61","author":"S-W Yang","year":"1998","unstructured":"Yang S-W, Zhou B-N, Wisse JH, Evans R, van der Werff H, Miller JS, et al. Three new ellagic acid derivatives from the bark of Eschweilera coriacea from the suriname rainforest. J Nat Prod. 1998;61:901\u20136.","journal-title":"J Nat Prod"},{"key":"5445_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.indcrop.2019.05.012","volume":"137","author":"AR de Araujo","year":"2019","unstructured":"de Araujo AR, Ramos-Jesus J, de Oliveira TM, de Carvalho AMA, Nunes PHM, Daboit TC, et al. Identification of eschweilenol C in derivative of Terminalia fagifolia Mart. and Green synthesis of bioactive and biocompatible silver nanoparticles. Ind Crops Prod. 2019;137:52\u201365.","journal-title":"Ind Crops Prod"},{"key":"5445_CR29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0020-7519(97)00080-5","volume":"27","author":"W Trager","year":"1997","unstructured":"Trager W, Jensen JB. Continuous culture of Plasmodium falciparum: its impact on malaria research. Int J Parasitol. 1997;27:989\u20131006.","journal-title":"Int J Parasitol"},{"key":"5445_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2307\/3280287","volume":"65","author":"C Lambros","year":"1979","unstructured":"Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418\u201320.","journal-title":"J Parasitol"},{"key":"5445_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12936-015-0718-z","volume":"14","author":"J Reader","year":"2015","unstructured":"Reader J, Botha M, Theron A, Lauterbach SB, Rossouw C, Engelbrecht D, et al. Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malar J. 2015;14:213.","journal-title":"Malar J"},{"key":"5445_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4269\/ajtmh.1993.48.205","volume":"48","author":"MT Makler","year":"1993","unstructured":"Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg. 1993;48:205\u201310.","journal-title":"Am J Trop Med Hyg"},{"key":"5445_CR33","doi-asserted-by":"publisher","first-page":"114669","DOI":"10.1016\/j.ab.2022.114669","volume":"648","author":"PVT Fokou","year":"2022","unstructured":"Fokou PVT, Tali BMT, Dize D, Mbouna CDJ, Ngansop CAN, Keumoe R, et al. Implementation and continued validation of the malaria Plasmodium falciparum lactate dehydrogenase-based colorimetric assay for use in antiplasmodial drug screening. Anal Biochem. 2022;648:114669.","journal-title":"Anal Biochem"},{"key":"5445_CR34","first-page":"55","volume":"7","author":"YF Kazi","year":"1994","unstructured":"Kazi YF, Parton R, Memon BA. Haemolytic assay for the detection of adenylate cyclase toxin of Bordetella pertussis. Pak J Pharm Sci. 1994;7:55\u2013559.","journal-title":"Pak J Pharm Sci"},{"key":"5445_CR35","doi-asserted-by":"publisher","first-page":"e1001169","DOI":"10.1371\/journal.pmed.1001169","volume":"9","author":"M Delves","year":"2012","unstructured":"Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Elizabeth A, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012;9:e1001169.","journal-title":"PLoS Med"},{"key":"5445_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/AAC.44.1.88-96.2000","volume":"44","author":"T Akompong","year":"2000","unstructured":"Akompong T, Ghori N. In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2000;44:88\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"5445_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1475-2875-12-424","volume":"12","author":"C Le Manach","year":"2013","unstructured":"Le Manach C, Scheurer C, Sax S, Schleiferb\u00f6ck S, Cabrera DG, Younis Y, et al. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J. 2013;12:424.","journal-title":"Malar J"},{"key":"5445_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijpddr.2016.02.004","volume":"6","author":"BF Roberts","year":"2016","unstructured":"Roberts BF, Iyamu ID, Lee S, Lee E, Ayong L, Kyle DE, et al. Spirocyclic chromanes exhibit antiplasmodial activities and inhibit all intraerythrocytic life cycle stages. Int J Parasitol Drugs Drug Resist. 2016;6:85\u201392.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5445_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijpddr.2017.02.002","volume":"7","author":"BF Roberts","year":"2017","unstructured":"Roberts BF, Zheng Y, Cleaveleand J, Lee S, Lee E, Ayong L, et al. 4-Nitro styrylquinoline is an antimalarial inhibiting multiple stages of Plasmodium falciparum asexual life cycle. Int J Parasitol Drugs Drug Resist. 2017;7:120\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5445_CR40","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.","journal-title":"Sci Rep"},{"key":"5445_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49:5\u201314.","journal-title":"Nucleic Acids Res"},{"key":"5445_CR42","doi-asserted-by":"publisher","first-page":"e45906","DOI":"10.1371\/journal.pone.0045906","volume":"7","author":"PN Soh","year":"2012","unstructured":"Soh PN, Witkowski B, Gales A, Huyghe E, Berry A, Pipy B. Implication of glutathione in the in vitro antiplasmodial mechanism of action of ellagic acid. PLoS ONE. 2012;7:e45906.","journal-title":"PLoS ONE"},{"key":"5445_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fmicb.2017.00496","volume":"8","author":"BM Fontaine","year":"2017","unstructured":"Fontaine BM, Nelson K, Lyles JT, Jariwala PB, Garc\u00eda-rodriguez JM, Quave CL, et al. Identification of ellagic acid rhamnoside as a bioactive component of a complex botanical extract with anti-biofilm activity. Front Microbiol. 2017;8:496.","journal-title":"Front Microbiol"},{"key":"5445_CR44","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1021\/acsinfecdis.1c00373","volume":"7","author":"J Niemand","year":"2021","unstructured":"Niemand J, Biljon V, Der WV, Van HA, Reader J. Chemogenomic fingerprints associated with stage-specific gametocytocidal compound action against human malaria parasites. ACS Infect Dis. 2021;7:2904\u201316.","journal-title":"ACS Infect Dis"},{"key":"5445_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1017\/S0031182004005888","volume":"129","author":"J Krungkrai","year":"2004","unstructured":"Krungkrai J. The multiple roles of the mitochondrion of the malarial parasite. Parasitology. 2004;129:511\u201324.","journal-title":"Parasitology"},{"key":"5445_CR46","first-page":"2976","volume":"4","author":"H Sor\u00e9","year":"2018","unstructured":"Sor\u00e9 H, Alessandro SD, Sanon S, Parapini S, Tiono A, Valea I, et al. In vitro inhibitory activity against Plasmodium falciparum sexual and asexual stages of medicinal plants used in Burkina. Int J Curr Pharm Res. 2018;4:2976\u201383.","journal-title":"Int J Curr Pharm Res"},{"key":"5445_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0006-2952(03)00396-4","volume":"66","author":"E Deharo","year":"2003","unstructured":"Deharo E, Barkan D, Krugliak M, Golenser J, Ginsburg H. Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels. Biochem Pharmacol. 2003;66:809\u201317.","journal-title":"Biochem Pharmacol"},{"key":"5445_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1042\/bj20020793","volume":"365","author":"TJ Egan","year":"2002","unstructured":"Egan TJ, Combrinck JM, Egan J, Hearne GR, Marques HM, Ntenteni S, et al. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J. 2002;365:343\u20137.","journal-title":"Biochem J"},{"key":"5445_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.molbiopara.2007.11.005","volume":"157","author":"TJ Egan","year":"2008","unstructured":"Egan TJ. Haemozoin formation. Mol Biochem Parasitol. 2008;157:127\u201336.","journal-title":"Mol Biochem Parasitol"},{"key":"5445_CR50","doi-asserted-by":"publisher","first-page":"015","DOI":"10.1093\/femspd\/ftac015","volume":"80","author":"M Mariebernard","year":"2022","unstructured":"Mariebernard M, Mohanty A, Rajendran V. A comprehensive review on classifying fast-acting and slow-acting antimalarial agents based on time of action and target organelle of Plasmodium sp. Pathog Dis. 2022;80:015.","journal-title":"Pathog Dis"},{"key":"5445_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4269\/ajtmh.15-0007","volume":"93","author":"L Cui","year":"2015","unstructured":"Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. Antimalarial drug resistance: literature review and activities and findings of the ICEMR network. Am J Trop Med Hyg. 2015;93:57\u201368.","journal-title":"Am J Trop Med Hyg"},{"key":"5445_CR52","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1073\/pnas.1104063108","volume":"108","author":"N Klonis","year":"2011","unstructured":"Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA. 2011;108:11405\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5445_CR53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/415673a","volume":"415","author":"LH Miller","year":"2002","unstructured":"Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;415:673\u20139.","journal-title":"Nature"},{"key":"5445_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: Linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23:917\u201328.","journal-title":"Nat Med"},{"key":"5445_CR55","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1128\/AAC.01175-08","volume":"53","author":"PN Soh","year":"2009","unstructured":"Soh PN, Witkowski B, Olagnier D, Nicolau M, Berry A. In vitro and in vivo properties of ellagic acid in malaria treatment. Antimicrob Agents Chemother. 2009;53:1100\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"5445_CR56","doi-asserted-by":"publisher","first-page":"e80813","DOI":"10.7554\/eLife.80813","volume":"11","author":"RCS Edgar","year":"2022","unstructured":"Edgar RCS, Siddiqui G, Hjerrild K, Malcolm TR, Vinh NB, Webb CT, et al. Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway. Elife. 2022;11:e80813.","journal-title":"Elife"},{"key":"5445_CR57","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.cclet.2021.09.102","volume":"33","author":"AK Marapaka","year":"2022","unstructured":"Marapaka AK, Sankoju P, Zhang G, Ding Y, Ma C, Pillalamarri V, et al. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: bological evaluation and structural characterization by cocrystallization. Chin Chem Lett. 2022;33:2550\u20134.","journal-title":"Chin Chem Lett"},{"key":"5445_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1475-2875-7-161","volume":"7","author":"SB Lauterbach","year":"2008","unstructured":"Lauterbach SB, Coetzer TL. The M18 aspartyl aminopeptidase of Plasmodium falciparum binds to human erythrocyte spectrin in vitro. Malar J. 2008;7:161.","journal-title":"Malar J"},{"key":"5445_CR59","first-page":"1905","volume":"49","author":"NH Zakaria","year":"2020","unstructured":"Zakaria NH, Hassan NI, Wai LK. Molecular docking study of the interactions between Plasmodium falciparum lactate dehydrogenase and 4-aminoquinoline hybrids. Pharmaceuticals. 2020;49:1905\u201313.","journal-title":"Pharmaceuticals"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05445-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:18:04Z","timestamp":1764181084000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05445-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5445"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05445-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"type":"electronic","value":"1475-2875"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human blood used in this study was collected from a group of volunteers who provided informed consent. The Joint Institutional Review Board for Animal & Human Bioethics (JIRB) approved the protocol at the University of Yaound\u00e9 1, Cameroon under note BTC-JIRB2023-091. All methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}